Broad Institute Chemical Biology Platform Data and Protocol Sharing Agreement
(to be signed annually)

Dear Contributing Scientist,

If your application to screen or to deposit compounds is approved, the Broad Institute of Harvard and MIT Chemical Biology (BCB) Platform will offer you the opportunity to interact with us. Chemists will be able to deposit compounds to be screened by a number of researchers, including researchers from institutions other than Harvard and MIT. Biologists will be able to screen a range of small molecules from different sources, including compounds deposited by contributing chemists. The core funding for the BCB Platform comes from a government contract, the National Cancer Institute (NCI) Initiative for Chemical Genetics (ICG), which carries certain restrictions on how funds can be used for the benefit of individual companies. For this reason, we need to understand whether your research is funded by grants that carry "strings", and we need to be very clear about our mutual expectations for how data will be shared and published. In particular, to make sure that your deposit of data into a shared database does not constitute "publication" for patent purposes, all users of this database need to have a clear understanding of how it may be used. This document is our attempt to clarify all of these issues in a way that maximizes your ability to use the collective experience of ICG and Broad Institute scientists to make progress on your project. Please understand that by signing below, you agree to all terms stated. Failure to follow these terms will result in a termination of future relationships with the ICG.

Sincerely,

Nicola Tolliday, Ph.D.
Head of Screening, Broad Institute Chemical Biology Platform and ICG
Tim Lewis, Ph.D.
Head of Synthetic Chemistry, Broad Institute Chemical Biology Platform and ICG

Funding of your project

1. Is this work funded by corporate grants?
If so, please specify _____

2. Is this work funded by a foundation?
If so, please specify_____

Materials

Does your assay include any materials that you received from someone else under a material transfer agreement (MTA)?
If so, please specify_____

Intellectual Property

Do any pre-commitments of intellectual property relating to the compounds that you are submitting or relating to your screening project(s) exist? Please consider this question carefully as many sponsor-funded agreements and MTAs include provisions about intellectual property (including, for example, options or license grants). If any pre-commitments exist, or if you would

like assistance in determining whether they exist, please contact Erik Halvorsen, Director of Business Development (erik_halvorsen@harvard.edu) in the Harvard University Office of Technology Development.

• By signing this form, I am saying that no pre-commitments of intellectual property exist for my contributed compounds and/or my screening project(s), and that I agree to alert the ICG (Nicola Tolliday/Tim Lewis and Erik Halvorsen) if this condition changes. Furthermore, I agree to notify the ICG of any patents filed on my compounds and/or resulting from my screening project(s). The ICG will not necessarily require rights to these patents, but needs to be made aware of these patent applications for reporting requirements to NCI.

Data Sharing

• By using the BCB Screening Facility, I agree to participate in the ICG community of scientists and, in particular, to share with other ICG and Broad Institute community members what I learn during the course of my project(s). Furthermore, I recognize that the structures of my contributed compounds and/or the screening data that I collect may be useful for purposes other than the immediate intent of my project(s).

Data Sharing within the ICG

• I agree to provide my chemical synthesis protocol(s), screening protocol(s) and data obtained from my screening project(s) for deposit into a database shared with the community of scientists who sign this agreement ("pre-*ChemBank*") in a timely manner, during or immediately following my visit to the BCB Screening Facility. I understand that this database is accessible to other academic scientists who have deposited compounds and/or screening data, as well as to the ICG computational science and software development groups.

• I agree to hold in confidence all data that I learn, download or print from pre-*ChemBank* until such data are publicly available, so that deposit of data into this database does not constitute public disclosure. In this way, those who deposit data, including myself, can preserve their ability to publish or patent the results of their work if they so choose. I understand that I may discuss ICG data with members of my laboratory provided that I inform them that the data are confidential and must not be shared with others outside the laboratory until they are publicly available.

• I agree to share follow-up assay data with the ICG every 6 months for deposit into pre-*ChemBank*. Follow-up data may be used by chemists and screeners to design new chemical structures, to prioritize specific classes of screening positives, to identify screening positives that are active in multiple assays, or to suggest possible mechanisms of action for compounds. Follow-up data include:

- new compounds made to probe the mechanism of an initial screening positive
- methods and output of additional data-analysis activities
- criteria, such as thresholds, for screening positive selection
- lists of screening positives, retested compounds, and re-ordered compounds
- results of follow-up experiments

• If a dispute arises about the ownership of data or the priority of the discovery of a screening positive, I agree to discuss the dispute with the Directors of ICG and abide by their decision.

Data Sharing outside the ICG

A major purpose of the ICG, funded by the National Cancer Institute, is the development of a publicly accessible database of information on the biological activity of small molecules (*ChemBank; chembank.broad.harvard.edu)*. An important source of data for this public database will be results from chemical-genetic screens carried out at the ICG and at the Broad Institute of Harvard and MIT.

• I hereby authorize public release in *ChemBank* of the compound structures, synthetic pathways, screening protocols and data generated and analyzed in high throughput screens as soon as the compound structures and/or screening results are published, or 1 year from completion of the screen, whichever is the sooner. A screen is considered "complete" as soon as a screener finishes their visit to the BCB Screening Facility to collect HTS data. Six-month extensions may be granted in select cases with permission from the ICG; these extensions are intended only for cases where the collaborating scientist demonstrates a need for additional time in order to finish an impending publication or patent application. The ICG will make reasonable efforts to inform me when my structures and/or screening data are to be made public.

• I agree that follow-up data that I deposit in pre-*ChemBank* will be released for public access through *ChemBank* simultaneously with the raw data unless I explicitly request, in writing at least 1 month before publication/release of the raw data, that selected follow-up data be reserved to allow me to prepare additional papers or patent applications. Under these circumstances, the release of these "deferred" data may be delayed for up to 1 year, or until publication, whichever is sooner. Again, six month extensions may be offered by the ICG in select cases, if specifically requested.

• I understand that data in pre-*ChemBank* will be examined for the purposes of global analysis by the ICG computational science group, such as statistical comparisons of frequencies of screening positives across different types of screens or different types of small-molecule collections. I agree that the results of such global analyses may be made public at any time, provided that the details of my synthetic protocols and/or screening approaches, and the specific structures of my screening positives are not also released. The ICG will do its best to inform me when such information, abstracted from my screen(s), is made public.

Publication

In any collaboration, it is very important that the collaborating organizations and scientists receive the appropriate acknowledgment and authorship. Since use of the BCB Screening Facility is funded by the NCI and the Broad Institute of Harvard and MIT, both organizations must be acknowledged. In addition, the standard rules of academic authorship apply: intellectual contribution requires co-authorship. Use of the BCB Screening Facility by itself does not necessarily require co-authorship, however.

• I understand that any work performed with the support of the ICG must be formally acknowledged in all presentations and publications. Specifically, I agree to place *at a minimum* the following text (without modification) directly into the acknowledgement section of any such publications:

"We wish to thank the National Cancer Institute and the Initiative for Chemical Genetics, who provided support for this publication, and the Chemical Biology Platform of the Broad Institute of Harvard and MIT for their assistance in this work."

• Additional acknowledgments or co-authorship may be required, depending on the degree and extent of contribution by others. In cases where significant intellectual contribution has been made to my project (*e.g.*, novel chemistry, assay methods, screening strategies, data analysis methods, *etc.*), I agree to grant co-authorship to the appropriate scientists. If co-authorship is not required, I agree to acknowledge other researchers, as appropriate, if their work has contributed to a paper I write, or a presentation I give. In general, when there is any question about proper attribution, I will contact Nicola Tolliday or Tim Lewis for guidance.

• I agree to not publish or publicly disclose results derived from another researcher's unpublished chemistry or screening results without permission from the appropriate scientist(s) in writing or through email.

• I understand that a very powerful advantage of screening at the BCB Screening Facility is access to libraries of novel small-molecules, which have been produced by collaborating chemists from around the world and which have been demonstrated to have superior performance in several screening and follow-up chemistry contexts. These are considered research-enabling reagents that are a major intellectual contribution to any screening experience. Therefore, I agree to not publish or publicly disclose any details regarding novel, non-commercial small molecules that may have been screened without prior permission from the contributing chemist. Generally speaking, novel biological annotation of such small molecules requires co-authorship with the contributing chemist. Follow-up studies that do not disclose novel behavior of a previously published non-commercial compound usually do not require co-authorship, but the contributing chemist should be alerted to any such publications.

• Because tracking success of the ICG is important to the NIH and to future funding of the ICG, I agree to notify ICG if any work performed in the ICG facilities results in a publication or patent.

Acknowledged and Agreed:

Signature of Screening Room User	Printed name	Date

Signature of Principal Investigator	Printed name	Date

Please send signed forms to:

Initiative for Chemical Genetics
Broad Institute of Harvard and MIT
320 Bent Street
Cambridge, MA 02141

or fax them to “Initiative for Chemical Genetics” at (617) 324-9601.

Please send questions about this agreement to bcbScreenApply@broad.harvard.edu.